24th week of 2015 patent applcation highlights part 20 |
Patent application number | Title | Published |
20150158851 | PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Provided herein are compounds of formula (AA): | 2015-06-11 |
20150158852 | INDUSTRIAL METHOD FOR THE PREPARATON OF HIGH-PURITY METHIOZOLIN - Provided is an industrial method for the preparation of [5-{(2,6-difluorobenzyloxy)methyl}-4,5-dihydro-5-methyl-3-(3-methylthiophene-2-yl)-isoxazole](common name: methiozolin) represented by Formula 1 that is a herbicidal substance in high-purity. | 2015-06-11 |
20150158853 | CYTOCHROME P450 INHIBITORS AND USES THEREOF - The present invention provides compounds having the general structural formula (I) | 2015-06-11 |
20150158854 | QUINAZOLINE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF - A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) | 2015-06-11 |
20150158855 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS - The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I) | 2015-06-11 |
20150158856 | AMIDE OR UREA CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE - The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments. | 2015-06-11 |
20150158857 | BENZHYDRYL DERIVATIVES - Compounds having a benzhydryl structure represented by formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for treating diseases of the respiratory tract. | 2015-06-11 |
20150158858 | HETEROARYL DERIVATIVES - Compounds of formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction. | 2015-06-11 |
20150158859 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein. | 2015-06-11 |
20150158860 | CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF - The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions. | 2015-06-11 |
20150158861 | CYTOMEGALOVIRUS INHIBITOR COMPOUNDS - Compounds of Formula (I) wherein n, m, R | 2015-06-11 |
20150158862 | 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS - The present invention is concerned with novel 4-substituted 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles having formula (I) | 2015-06-11 |
20150158863 | HETEROCYCLIC COMPOUND - The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. | 2015-06-11 |
20150158864 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES - The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK. | 2015-06-11 |
20150158865 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2015-06-11 |
20150158866 | Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones - The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds. | 2015-06-11 |
20150158867 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE - The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes. | 2015-06-11 |
20150158868 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE - The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. | 2015-06-11 |
20150158869 | PYRROLOBENZODIAZEPINES AS UNSYMMETRICAL DIMERIC PBD COMPOUNDS FOR INCLUSION IN TARGETED CONJUGATES - A compound with the formula I wherein: R | 2015-06-11 |
20150158870 | POLYMORPHS OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-- YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE - The present invention provides individual crystalline polymorphs of 7-(tert-Butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine designated Form 1, Form 3 and Form 4. Each polymorph disclosed herein is characterized according to one or more of (a) powder X-ray diffraction data (“XRPD”); (b) differential scanning calorimetry (“DSC”); and (e) thermogravimetric analysis (TGA). | 2015-06-11 |
20150158871 | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR - Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2015-06-11 |
20150158872 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE - The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. | 2015-06-11 |
20150158873 | BROMODOMAIN INHIBITORS - The present invention provides for compounds of formula (I) | 2015-06-11 |
20150158874 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF - The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders. | 2015-06-11 |
20150158875 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS - The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold. | 2015-06-11 |
20150158876 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS - Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 2015-06-11 |
20150158877 | DUALISTIC SUBSTITUTED PHTHALOCYANINE ZINC FORMULA, PROCESS OF SEPARATING THE SAME AND USE THEREOF - The invention discloses a pharmaceutical formula used in photodynamic therapy (PDT) for cancer or precancerous lesions. The formula includes four components of disulfonic acid diphthaloyl iminomethyl dualistic substituted phthalocyanine zinc alkali salt. Furthermore, this invention also provides an industrial chromatography separation process. These components is obtained by separating ten cis isomers of ZnPcS2P2 from synthetic products and then separating among them 4 isomers with significant amphiphilic property. It is evident that 4 isomers of the invention shows improved drug affect compared to formulas containing those 10 cis-isomers. | 2015-06-11 |
20150158878 | BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS - The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, | 2015-06-11 |
20150158879 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection - The invention provides novel compounds having the general formula: | 2015-06-11 |
20150158880 | TAXANE AND ABEO-TAXANE ANALOGS - The present application discloses new taxane analogs, intermediates and methods for producing them. The present application is also directed to pharmaceutical formulations comprising abeo-taxanes and methods of treating cancer with the abeo-taxanes. | 2015-06-11 |
20150158881 | METHODS USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS - In general, the present invention features improved methods useful for the synthesis of analogs of halichondrin B, such as eribulin and pharmaceutically acceptable salts thereof (e.g., eribulin mesylate). | 2015-06-11 |
20150158882 | HETEROCYCLIC COMPOUND - Provided is a compound useful for the prophylaxis or treatment of cancer. | 2015-06-11 |
20150158883 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS - The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I), | 2015-06-11 |
20150158884 | HISTONE DEACETYLASE INHIBITORS - This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3). | 2015-06-11 |
20150158885 | SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS - Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders. | 2015-06-11 |
20150158886 | CYCLIC DINUCLEOSIDES - Provided herein are compounds of formula Ia: | 2015-06-11 |
20150158887 | Process For The Preparation Of Chelated Compounds - The present invention generally relies on a process for the preparation of chelated compounds, comprising the selective interaction between a solid matrix and a chelating agent. In more details, the present invention enables the preparation of chelated compounds useful as diagnostic agents, in high yields and in a reliable way. | 2015-06-11 |
20150158888 | BODIPY Derivatives and Methods of Synthesis and Use Thereof - Derivatives of BODIPY (boron dipyrromethene difluoride) and their synthesis and use are disclosed. | 2015-06-11 |
20150158889 | HYDROPHILIC SILICONE COMPOSITION - A composition comprising a carbocyclic group and a hydrophilic moiety attached thereto an alpha, beta-unsaturated organosilicon compound. Such compounds are useful in developing water absorbing silicone-hydrogel films. Silicone-hydrogel films provide increased oxygen to pass through a lens or other treated materials. | 2015-06-11 |
20150158890 | Method Of Preparing An Organohalosilane - The application relates to a method for preparing organohalosilanes in a two-step process: Steps (i) contacting a copper catalyst with hydrogen gas and halogenated silanes forming a silicon-containing copper catalyst; and Step (ii) contacting said silicon-containing copper catalyst with an organohalide to form the organohalosilane. | 2015-06-11 |
20150158891 | STABLE PHARMACEUTICAL COMPOSITION FOR OPTIMIZED DELIVERY OF AN HIV ATTACHMENT INHIBITOR - A pharmaceutical composition contains the compound 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, and hydroxypropyl methyl cellulose (HPMC) having a viscosity of at least about 100 cP, wherein the composition does not contain any enzyme inhibitors. | 2015-06-11 |
20150158892 | HYDROLYSIS CATALYST AND PROCESS - A process of hydrolyzing a monodentate, bidentate or tridentate phosphorus-based phosphite ester ligand or ligand blend for a transition metal catalyst comprising contacting the ligand or ligand blend with a hydrolysis catalyst of the formula (R | 2015-06-11 |
20150158893 | PROCESS FOR PREPARING MALATHION FOR PHARMACEUTICAL USE - The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes. | 2015-06-11 |
20150158894 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF - The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof. | 2015-06-11 |
20150158895 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) - The invention relates to compounds of the formula | 2015-06-11 |
20150158896 | NOVEL RUTHENIUM COMPLEXES, THEIR USE IN THE METATHESIS REACTIONS, AND A PROCESS FOR CARRYING OUT THE METATHESIS REACTION - The invention is related to the metal complexes of the general formula (1). The invention is related also to the use of metal complexes of the formula 1 as (pre)catalysts for the olefin metathesis reactions, as well as to the process for carrying out the olefin metathesis reaction. | 2015-06-11 |
20150158897 | COBALT PYROPHOSPHATE COMPLEXES AND METHODS OF TREATMENT USING THE COMPLEXES - The present invention involves pyrophosphate bridged coordination complexes and the treatment of medical conditions, such as cancer, using the pyrophosphate bridged coordination complexes. The pyrophosphate bridged coordination complexes include four new compounds, [Co(phen) | 2015-06-11 |
20150158898 | LIGNIN-BASED SURFACTANTS - Methods for converting waste streams from the wood pulping industry to high-value surfactants are described. For example, isolated lignin and lignosulfonate or waste streams containing lignin and lignosulfonate can be directly converted to surfactants, or they can be first converted to methylol derivatives and treated with further reagents to produce surfactants. | 2015-06-11 |
20150158899 | 2,3-Fluorinated Glycosides as Neuraminidase Inhibitors and Their Use as Anti-Virals - Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza. | 2015-06-11 |
20150158900 | METHOD FOR 2-SULFATION OF GLYCOSIDES - Method for selective 2-sulfation of glycosides. | 2015-06-11 |
20150158901 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME - The present invention provides macrocyclic compounds useful as therapeutic agents of the formula: | 2015-06-11 |
20150158902 | MATRICES AND MEDIA FOR STORAGE AND STABILIZATION OF BIOMOLECULES - The present invention provides compositions useful for biomolecule storage comprising a water soluble inorganic compound, a stabilizer, or a combination thereof. The present invention also provides methods of using the compositions of the invention to store biomolecules in the dry state and in solution, as well as sample carriers and kits comprising compositions of the invention. | 2015-06-11 |
20150158903 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF - Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L | 2015-06-11 |
20150158904 | SYNTHESIS OF TANTALUM SOL-GEL AND PRODUCTION METHOD OF MICROEXTRACTION SYRINGE FOR THE PURPOSE OF ENRICHMENT OF PHOSPHOPEPTIDES - The present invention relates to a production method of sol-gel ( | 2015-06-11 |
20150158905 | Isolation of Cysteine Containing Peptides - The disclosure provides a capture system and methods for isolating cysteine-containing peptides from biological fluid and proteolytic mixtures. The disclosure also provides compounds of formulae (II), (III), and (IV), useful in methods of the invention. | 2015-06-11 |
20150158906 | Method of Purifying Therapeutic Proteins - The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising:
| 2015-06-11 |
20150158907 | METHODS AND SYSTEMS FOR PROCESSING A CELL CULTURE - Provided herein are methods of processing a cell culture and open circuit filtration systems. | 2015-06-11 |
20150158908 | SMAC Mimetic for Treating Myelodysplastic Syndromes - A SMAC mimetic and pharmaceutical compositions thereof and methods of use. | 2015-06-11 |
20150158909 | ANTI-VIRAL COMPOUNDS - The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection. | 2015-06-11 |
20150158910 | PAR4 AGONIST PEPTIDES - The present invention provides PAR4 agonist peptides. These peptides are useful for developing robust PAR4 receptor assays. | 2015-06-11 |
20150158911 | PIGMENT STRUCTURES, PIGMENT GRANULES, PIGMENT PROTEINS, AND USES THEREOF - The present invention is based, at least in part, on the isolation of intact pigment granules from the brown chromatophores in the skin of the cuttlefish, | 2015-06-11 |
20150158912 | TREATMENT OF IL-17 MEDIATED DISEASE BY BLOCKING SEFIR-SEFIR INTERACTIONS - A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. In particular, it has been determined that the αC helix region of the SEFIR domain of both IL-17R and Act1 plays an important role in the association of IL-17R and Act1. To facilitate cell permeation, the decoy peptide is preferably conjugated to a protein transduction domain. Examples of IL-17 mediated diseases include various human and animal inflammatory and autoimmune diseases such as asthma. | 2015-06-11 |
20150158913 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY - Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed. | 2015-06-11 |
20150158914 | PEPTIDES, CONSTRUCTS AND USES THEREFOR - Novel peptides and constructs for carrying compounds across a cell membrane. Also provided are methods for carrying compounds across the cell membrane, antagonizing or destroying X-protein of HBV, treatment and/or management of HBV infection, treatment and/or prevention of HCC, and degradation of a target protein. | 2015-06-11 |
20150158915 | Compstatin Analogs with Improved Pharmacokinetic Properties - Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed. | 2015-06-11 |
20150158916 | COMPOSITIONS, METHODS AND USES - The present invention relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for the treatment of disease in mammals including humans. | 2015-06-11 |
20150158917 | NOVEL TOXIN IN TYPE A CLOSTRIDIUM PERFRINGENS - The present disclosure relates to a novel toxin of Type A | 2015-06-11 |
20150158918 | NOVEL PLANT DEFENSINS AND USE IN THE TREATMENT OF PROLIFERATIVE DISEASES - The present invention relates to compositions and methods for preventing or treating proliferative diseases. In particular, the present invention relates to the use of compositions derived or derivable from plants, such as plant defensins, particularly in methods for the prevention or treatment of proliferative diseases such as cancer. The present invention also relates to associated uses, systems and kits. | 2015-06-11 |
20150158919 | NOVEL BIOACTIVE PROTEIN ISOLATED FROM CHINESE YAM AND USES THEREOF - A protein isolated from the Chinese yam | 2015-06-11 |
20150158920 | TRANSGENIC PLANTS EXPRESSING COBALAMIN BINDING PROTEINS - The present invention relates to the use of transgenic plants for the expression of vitamin B12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin B12 binding proteins. The present invention also relates to the use of recombinant vitamin B12 binding proteins from plants in analytical tests and treatment of vitamin B12 deficiency. Also disclosed is a method for purification of recombinant vitamin B12 binding proteins. | 2015-06-11 |
20150158921 | AlphaO-SUPERFAMILY CONOTOXIN PEPTIDE, PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present invention pertains to fields of biochemistry and molecular biology, relates to an αO-superfamily conotoxin peptide, pharmaceutical composition thereof, preparation method and use thereof. The present invention further relates to a propeptide of the conotoxin peptide, nucleic acid construct thereof, expression vector and transformed cell thereof, and fusion protein thereof. The present invention further relates to a method for blocking acetylcholine receptors as well as a use of the conotoxin peptide in the manufacture of a medicament. The new αO-superfamily conotoxin peptide of the present invention is capable of specifically blocking acetylcholine receptor (nAChRs) (e.g., α9α10 nAChR), and NMDA receptor (e.g., NR2C NMDAR), and has activity for treatment of neuralgia, addiction, and activity for treatment of chemotherapy of cancers, breast cancer, lung cancer, wound healing, epilepsia, ischemia, and thus is promising in the manufacture of analgesic, a medicament for treatment of addiction, and a tool drug for neuroscience. | 2015-06-11 |
20150158922 | TRANSGENIC PLANTS EXPRESSING COBALAMIN BINDING PROTEINS - The present invention relates to the use of transgenic plants for the expression of vitamin B12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin B12 binding proteins. The present invention also relates to the use of recombinant vitamin B12 binding proteins from plants in analytical tests and treatment of vitamin B12 deficiency. Also disclosed is a method for purification of recombinant vitamin B12 binding proteins. | 2015-06-11 |
20150158923 | Follistatin Fusion Proteins and Uses Thereof - In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient. | 2015-06-11 |
20150158924 | Derivatisation of Erythropoietin (EPO) - The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 2015-06-11 |
20150158925 | METHODS OF MANAGING GRAFT VERSUS HOST DISEASE - This disclosure relates to the use of drugs to prevent graft versus host disease (GVHD) in a subject after, before, or during a hematopoietic stem cell transplant. In certain embodiments, the drugs are antagonist of vasoactive intestinal peptide signaling. In certain embodiments, the subject has a blood or bone marrow cancer or condition. | 2015-06-11 |
20150158926 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME - CTP-modified human growth hormone polypeptides and pharmaceutical formulations and pharmaceutical compositions comprising the same and methods of producing, and using the same are disclosed. | 2015-06-11 |
20150158927 | HLA G-MODIFIED CELLS AND METHODS - Disclosed herein are genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies. | 2015-06-11 |
20150158928 | FLT4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY - The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor. | 2015-06-11 |
20150158929 | FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions. | 2015-06-11 |
20150158930 | FACTOR VIII SEQUENCES - There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to SEQ ID NO: 4 and which comprises six asparagine residues. Also provided is a functional factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g. haemophilia A, and a method for the preparation of a parvoviral gene delivery vector. | 2015-06-11 |
20150158931 | CYSTEINE PROTEASE CAPTURING AGENTS - The invention concerns cysteine protease capturing agents capable of highly selective and irreversible binding of the corresponding cysteine protease. Such compounds may have utility in fundamental biological research and diagnostics, e.g. involving labeled or immobilized versions of such compounds, and they may also have potential utility in therapy, based on competitive inhibition of the cysteine protease, as will be readily apparent to those skilled in the art. The present inventors have discovered that such capturing agents can be obtained by modification of a cleavage fragment of a ‘natural’ substrate for the cysteine protease of interest, said modification involving the introduction of a propargyl moiety in such a way that the terminal alkyne group is positioned to allow for interaction with the free thiol group of the cysteine residue at the active site of the protease. | 2015-06-11 |
20150158932 | NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES - Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens. | 2015-06-11 |
20150158933 | HIV Antigens and Antibodies and Compositions, Uses and Methods Thereof - The present specification discloses HIV antigens, immunogenic compositions and medicaments comprising such HIV antigens, methods and uses for such HIV antigens and immunogenic compositions and medicaments for making a α-HIV antibody, as well as α-HIV antibodies, therapeutic compositions an medicaments comprising such α-HIV antibodies, and methods and uses for such α-HIV antibodies and therapeutic compositions and medicaments for treating an HIV-based disease. | 2015-06-11 |
20150158934 | BROADLY NEUTRALIZING VHH AGAINST HIV-1 - The invention relates to a novel class of broadly neutralizing anti-HIV antibodies, more specifically to broadly neutralizing heavy chain variable domain antibodies (VHH) and variants and modifications thereof. The invention further relates to methods for producing these antibodies and to the use of the antibodies for diagnostic and therapeutic and/or prophylactic treatment of individuals that are infected with HIV, or are at risk of becoming infected. | 2015-06-11 |
20150158935 | PROTECTIVE VACCINE BASED ON STAPHYLOCOCCUS AUREUS SA2493 PROTEIN - The present invention relates to methods of inducing an immune response to | 2015-06-11 |
20150158936 | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P - The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5). | 2015-06-11 |
20150158937 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS - Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease. | 2015-06-11 |
20150158938 | GREMLIN-1 ANTIBODY - The present invention relates to a Gremlin-1 antibody that inhibits Gremlin-1 in a manner independent of bone morphogenetic protein (BMP) or vascular endothelial growth factor receptor-2 (VEGFR-2), thus providing the effect of treating cancer. The antibody of the present invention inhibits cell migration, cell invasion and cell proliferation which are dependent on Gremlin-1, and therefore, can be effectively used in treating cancer or immune disease. | 2015-06-11 |
20150158939 | Methods and Compositions for the Treatment of Immune Disorders - The present invention provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of plexin-A4 activity, which results in reducing the plexin-A4 activity in the subject, and thereby treating the immune-related disorder. Inhibitors of plexin-A4 activity include, for example, plexin-A4 antibodies and plexin-A4 fusion proteins. The present invention further provides a method of treating an immune-related disorder in a subject, comprising administering to the subject an effective amount of an inhibitor of semaphorin-3A (Sema3A) activity, which results in reducing the Sema3A activity in the subject, thereby treating the immune-related disorder. Inhibitors of Sema3A activity include, for example, Sema3A antibodies and Sema3A fusion proteins. | 2015-06-11 |
20150158940 | USE OF ANTAGONISTS TARGETING METALLOTHIONEIN TO TREAT INTESTINAL INFLAMMATION - Metallothioneins are stress inducible proteins with modulating functions during inflammation. Antagonizing metallothioneins during gut inflammation reduces markers of inflammations and enhances recuperation of intestinal inflammation. | 2015-06-11 |
20150158941 | ANTI-MALARIAL COMPOSITIONS - This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of | 2015-06-11 |
20150158942 | ANTI-CCL2 ANTIBODIES FOR TREATMENT OF SCLERODERMA - The present invention provides, among other things, improved anti-CCL2 antibodies characterized with high affinity, potency, tissue selectivity and/or epitope specificity, and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions based on an anti-CCL2 antibody having an affinity of 10 | 2015-06-11 |
20150158943 | METHODS RELATED TO ADALIMUMAB - Production and bioanalytical characterization of determinative parameters of adalimumab is presented. | 2015-06-11 |
20150158944 | METHODS FOR CONTROLLING THE GALACTOSYLATION PROFILE OF RECOMBINANTLY-EXPRESSED PROTEINS - The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose. | 2015-06-11 |
20150158945 | DNA ENCODING AN ANTI-SYSTEM ASC AMINO ACID TRANSPORTER 2 (ASCT2) ANTIBODY - An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof. | 2015-06-11 |
20150158946 | Anti-TLR4 Antibodies and Methods of Use Thereof - This invention relates generally to anti-Toll-like Receptor 4 (TLR4 antagonists) including antibodies that specifically bind Toll-like Receptor 4 (TLR-4), to methods of using the anti-TLR4 antagonists as therapeutics and to methods of using the anti-TLR4 antagonists for inhibiting, delaying the progression of, or otherwise ameliorating a symptom of Graft-versus-Host disease (GvHD) and/or improving survival of GvHD subjects and/or transplanted biological materials in subjects. | 2015-06-11 |
20150158947 | C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER - This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer. | 2015-06-11 |
20150158948 | BISPECIFIC ANTI-CXCR7 IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS - The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumour growth. | 2015-06-11 |
20150158949 | FIXED DOSAGE REGIMENS FOR ANTI-TYPE I INTERFERON RECEPTOR (IFNAR) ANTIBODIES - The disclosure provides methods for treating a subject having a type I IFN-mediated disease or disorder comprising administration of a fixed does of an anti-interferon alpha receptor antibody. The disclosure also provides methods for suppressing a type I interferon (IFN) gene signature (GS) in a subject. In addition, the disclosure provides methods of prognosing or monitoring disease progression in a subject having a type I IFN-mediated disease or disorder, methods of predicting a dosage regimen, methods of identifying a candidate therapeutic agent, methods of identifying a patient as a candidate for a therapeutic agent, and methods of designating a personalized therapy. | 2015-06-11 |
20150158950 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2015-06-11 |